First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). Meeting Abstract

Industry Collaboration International Collaboration

author list

  • Chi, Kim N.; Agarwal, Neeraj; Bjartell, Anders; Chung, Byung Ha; Gomes, Andrea Juliana Pereira de Santana; Given, Robert W.; Soto, Alvaro Juarez; Merseburger, Axel Stuart; Ozguroglu, Mustafa; Uemura, Hirotsugu; Ye, Dingwei; Deprince, Kris; Naini, Vahid; Li, Jinhui; Cheng, Shinta; Yu, Margaret K.; Zhang, Ke; Larsen, Julie S.; McCarthy, Sharon Anne; Chowdhury, Simon

publication date

  • May 20, 2019


published in



  • 37


  • 15